Order Article Reprints

Berclaz LM, Altendorf-Hofmann A, Lindner LH, Burkhard-Meier A, Di Gioia D, Dürr HR, Klein A, Albertsmeier M, Schmidt-Hegemann N-S, Klauschen F, et al. TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS). Cancers. 2023; 15(10):2735. https://doi.org/10.3390/cancers15102735

Berclaz, Luc M., Annelore Altendorf-Hofmann, Lars H. Lindner, Anton Burkhard-Meier, Dorit Di Gioia, Hans Roland Dürr, Alexander Klein, Markus Albertsmeier, Nina-Sophie Schmidt-Hegemann, Frederick Klauschen, and et al. 2023. "TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)" Cancers 15, no. 10: 2735. https://doi.org/10.3390/cancers15102735

Berclaz, L. M., Altendorf-Hofmann, A., Lindner, L. H., Burkhard-Meier, A., Di Gioia, D., Dürr, H. R., Klein, A., Albertsmeier, M., Schmidt-Hegemann, N.-S., Klauschen, F., & Knösel, T. (2023). TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS). Cancers, 15(10), 2735. https://doi.org/10.3390/cancers15102735